<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00100997</url>
  </required_header>
  <id_info>
    <org_study_id>UCLA-0408048-01</org_study_id>
    <secondary_id>CDR0000407499</secondary_id>
    <secondary_id>CTC-CNF1010</secondary_id>
    <secondary_id>CTC-CNF1010-CML-04001</secondary_id>
    <nct_id>NCT00100997</nct_id>
  </id_info>
  <brief_title>17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate</brief_title>
  <official_title>A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Intravenously Administered CNF1010 )17-(Allylamino)-17-Demethoxygeldanamycin [17-AAG]) in Patients With Gleevec-Resistent Chronic Myelogenous Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as 17-N-allylamino-17-demethoxygeldanamycin, work&#xD;
      in different ways to stop the growth of cancer cells, either by killing the cells or by&#xD;
      stopping them from dividing. It may also stop the growth of cancer cells by blocking some of&#xD;
      the enzymes needed for cell growth.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of&#xD;
      17-N-allylamino-17-demethoxygeldanamycin in treating patients with chronic phase chronic&#xD;
      myelogenous leukemia that did not respond to imatinib mesylate.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose and dose-limiting toxicity of&#xD;
           17-N-allylamino-17-demethoxygeldanamycin (17-AAG), in terms of frequency, severity, and&#xD;
           duration of treatment-emergent adverse events, in patients with imatinib&#xD;
           mesylate-resistant Philadelphia chromosome (Ph)-positive chronic phase chronic&#xD;
           myelogenous leukemia.&#xD;
&#xD;
        -  Determine the pharmacokinetics of this drug and its primary metabolite&#xD;
           (17-amino-17-demethoxygeldanamycin) in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the hematologic response rate, in terms of WBC count, platelet count, and&#xD;
           assessment of blast cells in peripheral blood, in patients treated with this drug.&#xD;
&#xD;
        -  Determine the cytogenic response rate, in terms of Ph-positive progenitor cells in the&#xD;
           bone marrow, in patients treated with this drug.&#xD;
&#xD;
        -  Assess the effect of this drug on pharmacodynamic markers (i.e., CRKL phosphorylation,&#xD;
           BCR-ABL kinase activity, and BCR-ABL, RAF kinase, and HSP70 expression) in these&#xD;
           patients.&#xD;
&#xD;
      OUTLINE: This is an open label, dose-escalation, multicenter study.&#xD;
&#xD;
      Patients receive 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) IV over 15 minutes or 1&#xD;
      hour (depending on the dose administered) once on days 1, 4, 8, 11, 15, 18, 22, and 25.&#xD;
      Treatment repeats every 28 days for up to 3 courses in the absence of unacceptable toxicity&#xD;
      or disease progression. Eligible patients may receive additional courses of 17-AAG at the&#xD;
      discretion of the investigator.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of 17-AAG until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6&#xD;
      patients experience dose-limiting toxicity. Up to 10 additional patients are treated at the&#xD;
      MTD.&#xD;
&#xD;
      Patients are followed for 1 month.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 40 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">October 2006</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tanespimycin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of chronic phase chronic myelogenous leukemia&#xD;
&#xD;
               -  Philadelphia chromosome (Ph)-positive disease&#xD;
&#xD;
          -  Hematologic resistence after treatment with imatinib mesylate (400 mg per day or&#xD;
             maximum tolerated dose [MTD]) as defined by 1 of the following criteria:&#xD;
&#xD;
               -  Loss of complete hematologic response, defined as WBC count OR platelet count &gt;&#xD;
                  upper limit of normal (ULN) on 2 separate occasions at least 2 weeks apart that&#xD;
                  cannot be attributed to other etiologies&#xD;
&#xD;
               -  Absolute increase of â‰¥ 30% in Ph-positive cells while on a stable dose of&#xD;
                  imatinib mesylate for at least 6 months* NOTE: *Patients meeting this criterion&#xD;
                  are not eligible for enrollment into the expanded MTD cohort&#xD;
&#xD;
          -  Less than 15% blasts in peripheral blood or bone marrow AND &lt; 30% blasts and&#xD;
             promyelocytes in peripheral blood or bone marrow&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 6 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin &lt; 1.5 times ULN (3 mg/dL for patients with Gilbert's syndrome)&#xD;
&#xD;
          -  ALT or AST &lt; 2 times ULN&#xD;
&#xD;
          -  No known hepatitis positivity&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine &lt; 1.5 times ULN OR&#xD;
&#xD;
          -  Creatinine clearance &gt; 60 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No New York Heart Association class III or IV cardiac disease&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No severe debilitating pulmonary disease, including any of the following:&#xD;
&#xD;
               -  Dyspnea at rest&#xD;
&#xD;
               -  Significant shortness of breath&#xD;
&#xD;
               -  Chronic obstructive pulmonary disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 1 month after study&#xD;
             participation&#xD;
&#xD;
          -  No known HIV positivity&#xD;
&#xD;
          -  No psychological or social condition that would preclude study compliance&#xD;
&#xD;
          -  No addictive disorder that would preclude study compliance&#xD;
&#xD;
          -  No family problems that would preclude study compliance&#xD;
&#xD;
          -  No known allergy or sensitivity to soy or other excipient components of study drug&#xD;
&#xD;
          -  No other illness or condition that may affect safety of study treatment or evaluation&#xD;
             of study endpoints&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  More than 2 weeks since prior interferon&#xD;
&#xD;
          -  No concurrent interferon&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  More than 2 weeks since prior cytarabine (4 weeks for doses &gt; 100 mg)&#xD;
&#xD;
          -  More than 6 weeks since prior busulfan&#xD;
&#xD;
          -  No concurrent cytarabine&#xD;
&#xD;
          -  No concurrent hydroxyurea during the second study treatment course and beyond&#xD;
&#xD;
          -  No concurrent anagrelide during the second study treatment course and beyond&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 2 days since prior imatinib mesylate&#xD;
&#xD;
          -  More than 1 week since prior and no concurrent drugs that alter metabolism by&#xD;
             cytochrome P450 3A4, including the following:&#xD;
&#xD;
               -  Diltiazem&#xD;
&#xD;
               -  Nifedipine&#xD;
&#xD;
               -  Verapamil&#xD;
&#xD;
               -  Fluconazole&#xD;
&#xD;
               -  Itraconazole&#xD;
&#xD;
               -  Ketoconazole&#xD;
&#xD;
               -  Lovastatin&#xD;
&#xD;
               -  Simvastatin&#xD;
&#xD;
               -  Indinavir&#xD;
&#xD;
               -  Nelfinavir&#xD;
&#xD;
               -  Ritonavir&#xD;
&#xD;
               -  Alprazolam&#xD;
&#xD;
               -  Diazepam&#xD;
&#xD;
               -  Midazolam&#xD;
&#xD;
               -  Triazolam&#xD;
&#xD;
               -  Phenobarbital&#xD;
&#xD;
               -  Phenytoin&#xD;
&#xD;
               -  Carbamazepine&#xD;
&#xD;
               -  Azithromycin&#xD;
&#xD;
               -  Clarithromycin&#xD;
&#xD;
               -  Erythromycin&#xD;
&#xD;
               -  Rifampin&#xD;
&#xD;
               -  Rifamycin&#xD;
&#xD;
               -  Astemizole&#xD;
&#xD;
               -  Terfenidine&#xD;
&#xD;
               -  Amiodarone&#xD;
&#xD;
               -  Cimetidine&#xD;
&#xD;
               -  Cisapride&#xD;
&#xD;
               -  Cyclosporine&#xD;
&#xD;
               -  Grapefruit juice&#xD;
&#xD;
               -  Hypericum perforatum (St. John's wort)&#xD;
&#xD;
               -  Warfarin&#xD;
&#xD;
          -  More than 4 weeks since prior investigational drugs and recovered&#xD;
&#xD;
          -  No concurrent imatinib mesylate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Sawyers, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2005</verification_date>
  <study_first_submitted>January 7, 2005</study_first_submitted>
  <study_first_submitted_qc>January 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2005</study_first_posted>
  <last_update_submitted>July 9, 2013</last_update_submitted>
  <last_update_submitted_qc>July 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2013</last_update_posted>
  <keyword>chronic myelogenous leukemia, BCR-ABL1 positive</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

